Systemic amyloidosis: an aggressive evolution in a patient with relapsing polychondritis and monoclonal gammopathy of undetermined significance (MGUS) undergoing peritoneal dialysis

Thiago Cavalcanti Matos; William George Giusti Fischer; Rosa Maria Rodrigues Pereira; Andre Silva Franco

doi:10.4322/acr.2024.518

Clinical Case Report

Systemic amyloidosis: an aggressive evolution in a patient with relapsing polychondritis and monoclonal gammopathy of undetermined significance (MGUS) undergoing peritoneal dialysis

Thiago Cavalcanti Matos; William George Giusti Fischer; Rosa Maria Rodrigues Pereira; Andre Silva Franco

http://dx.doi.org/10.4322/acr.2024.518 Autops Case Rep, vol.14, e2024518, 2024

PDF

Downloads: 2

Abstract

Herein, we report the case of primary amyloidosis with multi-organ involvement in a female patient in her 50s. The patient had a history of relapsing polychondritis, chronic kidney disease, and monoclonal gammopathy of undetermined significance (MGUS). The clinical manifestations included neuropathic pain, sensorimotor polyneuropathy, intrahepatic cholestatic liver injury, gastrointestinal symptoms, dysautonomia, and myocardial thickening. Initial histologic evaluations of the abdominal fat pad aspirate and bone marrow biopsy were negative for amyloid deposition. However, due to a high index of suspicion, a second bone marrow biopsy was performed, confirming the presence of the amyloid protein. Given the patient's complex medical history, other types of amyloidosis, such as AA amyloidosis, AL amyloidosis, and ß2-microglobulin amyloidosis, should also be considered as differential diagnoses. The type of amyloid protein was subsequently identified through laser microdissection of amyloid fibrils followed by liquid chromatography–tandem mass spectrometry as AL-lambda (amyloid light-chain) amyloidosis. The patient presented unfavorable evolution, with progressive dysautonomia, being admitted to the ICU, culminating in refractory circulatory shock, and undergoing an empirical broad-spectrum antibiotic therapy. After a few days, she presented pulseless ventricular tachycardia, culminating in her death, before undergoing specific treatment. This article highlights the crucial role of precise identification in guiding appropriate therapeutic strategies for this complex, yet potentially severe, diseases.

Keywords

Amyloidosis, Paraproteinemias, Polyneuropathies, Autonomic Nervous System Diseases

References

1 Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369-77. http://doi.org/10.2147/CLEP.S39981. PMid:25378951.

2 Hazenberg BP. Amyloidosis: a clinical overview. Rheum Dis Clin North Am. 2013;39(2):323-45. http://doi.org/10.1016/j.rdc.2013.02.012. PMid:23597967.

3 Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol. 1994;8(3):627-34. http://doi.org/10.1016/S0950-3579(05)80119-0. PMid:7954866.

4 Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465-71. http://doi.org/10.1016/j.mayocp.2018.08.041. PMid:30713046.

5 Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525-32. http://doi.org/10.1111/bjh.12286. PMid:23480608.

6 Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12(1):974. http://doi.org/10.1186/1471-2458-12-974. PMid:23148499.

7 Dasari S, Theis JD, Vrana JA, et al. Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95(9):1852-64. http://doi.org/10.1016/j.mayocp.2020.06.029. PMid:32861330.

8 Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. Annu Rev Biochem. 2017;86(1):27-68. http://doi.org/10.1146/annurev-biochem-061516-045115. PMid:28498720.

9 Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol. 2006;17(2):546-55. http://doi.org/10.1681/ASN.2005020132. PMid:16382021.

10 Yamamoto S, James J, Maruyama H, Narit I. Dialysis-related amyloidosis: pathogenesis and clinical features in patients undergoing dialysis treatment. In: Feng D, editor. Amyloidosis. London: InTech; 2013. p. 67-83. http://doi.org/10.5772/53390.

11 Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med. 1986;29(11):376-85. PMid:3808140.

12 Rubinstein SM, Stockerl-Goldstein K. How to screen for monoclonal gammopathy in patients with a suspected amyloidosis. JACC CardioOncol. 2021;3(4):590-3. http://doi.org/10.1016/j.jaccao.2021.07.001. PMid:34729532.

13 Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585-603. http://doi.org/10.1016/j.rdc.2018.06.004. PMid:30274625.

Submitted date:
07/30/2024

Accepted date:
08/12/2024

Publication date:
09/27/2024

Systemic amyloidosis: an aggressive evolution in a patient with relapsing polychondritis and monoclonal gammopathy of undetermined significance (MGUS) undergoing peritoneal dialysis

Thiago Cavalcanti Matos; William George Giusti Fischer; Rosa Maria Rodrigues Pereira; Andre Silva Franco

Abstract

Keywords

References

Links

Share

Autops Case Rep